查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585644

生技藥品契約製造市場：按產品、平台、治療領域和業務規模分類 - 2025-2030 年全球預測

Biologics Contract Manufacturing Market by Product (Biosimilar, Insulin, Interferons), Platform (Mammalian, Microbial), Therapeutic Area, Scale of Operation - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生技藥品契約製造市場價值為228.2億美元，預計到2024年將達到265.3億美元，複合年成長率為16.74%，到2030年將達到674.4億美元。

生技藥品契約製造包括生技藥品。對於希望在無需對專業設施進行大量資本投資的情況下有效擴大生產規模的製藥和生物技術公司來說，該行業至關重要。生技藥品可應用於多種治療領域，包括腫瘤學、疫苗和自體免疫疾病，為人類和動物的健康做出貢獻。契約製造製造商是重要的合作夥伴，提供細胞培養、發酵、精製和分析測試等領域的專業知識。對生技藥品契約製造的需求源於對生技藥品的需求不斷成長、生物技術的進步以及對生產靈活性的需求以管理成本和產能問題。關鍵的市場成長要素包括慢性病盛行率上升、個人化醫療的日益採用以及一次性系統和連續製造等製造流程的技術進步。市場機會與服務產品的多樣化、新興市場的擴張以及生物相似藥開發的合作有關。然而，嚴格的監管要求、高昂的初始投資成本以及對高技能技術專業知識的需求等挑戰可能會限制成長。此外，潛在的供應鏈中斷和品管問題也帶來了額外的障礙。創新領域包括開發先進的細胞和基因治療製造技術、改進的製程分析技術以及最大限度地減少對環境影響的永續製造流程。由於技術的快速進步和監管環境的變化，市場充滿活力。為了充分利用商機，企業應專注於培養策略夥伴關係關係、投資技術升級以及擴大服務組合以涵蓋端到端解決方案。全面了解監管要求和強大的品管系統對於應對市場複雜性和實現永續成長至關重要。

主要市場統計
基準年[2023] 228.2億美元
預測年份 [2024] 265.3億美元
預測年份 [2030] 674.4億美元
複合年成長率（%） 16.74%

市場動態：快速發展的生技藥品契約製造市場的關鍵市場洞察

供需的動態交互作用正在改變生技藥品契約製造市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 對生物相似藥和疫苗生產的需求增加
    • 奇美電子持續投資擴大產能
    • 合約服務的主要好處包括節省成本和時間
  • 市場限制因素
    • 國家間貿易政策的變化
  • 市場機會
    • 一次性生物製程設備和解決方案的出現
    • 標靶治療的細胞和基因療法的需求不斷成長
  • 市場挑戰
    • 對智慧財產權和專利侵權的擔憂

波特的五力：駕馭生技藥品契約製造市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生技藥品契約製造市場的外部影響

外部宏觀環境因素在塑造生技藥品契約製造市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解生技藥品契約製造市場的競爭狀況

生技藥品契約製造市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生技藥品契約製造市場供應商的績效評估

FPNV定位矩陣是評估生技藥品契約製造市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃生技藥品契約製造市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對生技藥品契約製造市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對生物相似藥和疫苗生產的需求增加
      • 奇美電子持續擴大產能投資活動
      • 合約服務的主要好處包括節省成本和時間
    • 抑制因素
      • 國家間貿易政策的變化
    • 機會
      • 推出一次性生物製程設備和解決方案
      • 對標靶治療的細胞和基因治療的需求不斷增加
    • 任務
      • 對智慧財產權和專利侵權的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章生技藥品契約製造市場：依產品

  • 生物相似藥
  • 胰島素
  • 干擾素
  • 單株抗體
  • 重組激素
  • 疫苗

第7章生技藥品契約製造市場：依平台

  • 哺乳動物的
  • 微生物

第8章按治療領域分類的生技藥品契約製造市場

  • 自體免疫疾病
  • 心血管疾病
  • 感染疾病
  • 代謝性疾病
  • 神經病學
  • 腫瘤學
  • 眼科
  • 呼吸系統疾病

第9章按業務規模分類的生技藥品契約製造市場

  • 臨床
  • 商業的

第10章美洲生技藥品契約製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太生技藥品契約製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的生技藥品契約製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie, Inc.
  • Abzena Ltd.
  • Acino International AG
  • ADMA Biologics, Inc.
  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • Avid Bioservices, Inc.
  • Baxter International, Inc
  • Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
  • JSR Life Sciences, LLC by JSR Group
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group Ltd.
  • Midas Pharma GmbH
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co. Ltd.
  • Wacker Chemie AG
  • WuXi Biologics Co., Ltd.
Product Code: MRR-8C74ADFBFD4E

The Biologics Contract Manufacturing Market was valued at USD 22.82 billion in 2023, expected to reach USD 26.53 billion in 2024, and is projected to grow at a CAGR of 16.74%, to USD 67.44 billion by 2030.

Biologics contract manufacturing encompasses the outsourcing of production processes for biologics-complex molecules such as proteins, nucleic acids, or cells produced through biological processes. This industry is crucial for pharmaceutical and biotech companies seeking to scale production efficiently without significant capital investment in specialized facilities. The application of biologics spans various therapeutic areas, including oncology, vaccines, and autoimmune diseases, catering to both human and veterinary health. Contract manufacturers serve as key partners, offering expertise in areas such as cell culture, fermentation, purification, and analytical testing. The necessity for biologics contract manufacturing arises from the growing demand for biologics, advancements in biotechnology, and the need for flexibility in production to manage costs and capacity issues. Key market growth factors include the rising prevalence of chronic diseases, increasing adoption of personalized medicine, and technological advancements in manufacturing processes, such as single-use systems and continuous manufacturing. Opportunities in the market are tied to the diversification of service offerings, expansion in emerging markets, and collaboration on biosimilar development. However, challenges such as stringent regulatory requirements, high initial investment costs, and the need for highly skilled technical expertise can restrain growth. Furthermore, potential supply chain disruptions and quality control issues present additional hurdles. Innovation areas include the development of advanced cell and gene therapy manufacturing techniques, improvements in process analytical technologies, and sustainable manufacturing processes to minimize environmental impact. The market is dynamic, driven by rapid technological advancements and shifting regulatory landscapes. To capitalize on opportunities, companies should focus on fostering strategic partnerships, investing in technology upgrades, and expanding service portfolios to cover end-to-end solutions. A comprehensive understanding of regulatory requirements and a robust quality management system are crucial to navigating market complexities and achieving sustainable growth.

KEY MARKET STATISTICS
Base Year [2023] USD 22.82 billion
Estimated Year [2024] USD 26.53 billion
Forecast Year [2030] USD 67.44 billion
CAGR (%) 16.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Manufacturing Market

The Biologics Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for biosimilars and vaccine production
    • Ongoing investment activities by CMOs for capacity expansion
    • Key advantages such as cost and time saving offered by contract services
  • Market Restraints
    • Changing trade policies between countries
  • Market Opportunities
    • Emergence of single-use bioprocessing equipment & solutions
    • Rising demand for cell and gene therapies for targeted treatment
  • Market Challenges
    • Concerns over the breach of intellectual property and patents

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Manufacturing Market

A detailed market share analysis in the Biologics Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Manufacturing Market

A strategic analysis of the Biologics Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Acino International AG, ADMA Biologics, Inc., AGC Biologics, Ajinomoto Bio-Pharma Services, Avid Bioservices, Inc., Baxter International, Inc, Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, JSR Life Sciences, LLC by JSR Group, Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Midas Pharma GmbH, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., Wacker Chemie AG, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biosimilar, Insulin, Interferons, Monoclonal Antibodies, Recombinant Hormones, and Vaccines.
  • Based on Platform, market is studied across Mammalian and Microbial.
  • Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurology, Oncology, Ophthalmology, and Respiratory Disorders.
  • Based on Scale of Operation, market is studied across Clinical and Commercial.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for biosimilars and vaccine production
      • 5.1.1.2. Ongoing investment activities by CMOs for capacity expansion
      • 5.1.1.3. Key advantages such as cost and time saving offered by contract services
    • 5.1.2. Restraints
      • 5.1.2.1. Changing trade policies between countries
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of single-use bioprocessing equipment & solutions
      • 5.1.3.2. Rising demand for cell and gene therapies for targeted treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns over the breach of intellectual property and patents
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Contract Manufacturing Market, by Product

  • 6.1. Introduction
  • 6.2. Biosimilar
  • 6.3. Insulin
  • 6.4. Interferons
  • 6.5. Monoclonal Antibodies
  • 6.6. Recombinant Hormones
  • 6.7. Vaccines

7. Biologics Contract Manufacturing Market, by Platform

  • 7.1. Introduction
  • 7.2. Mammalian
  • 7.3. Microbial

8. Biologics Contract Manufacturing Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cardiovascular Diseases
  • 8.4. Infectious Diseases
  • 8.5. Metabolic Diseases
  • 8.6. Neurology
  • 8.7. Oncology
  • 8.8. Ophthalmology
  • 8.9. Respiratory Disorders

9. Biologics Contract Manufacturing Market, by Scale of Operation

  • 9.1. Introduction
  • 9.2. Clinical
  • 9.3. Commercial

10. Americas Biologics Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biologics Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biologics Contract Manufacturing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Abzena Ltd.
  • 3. Acino International AG
  • 4. ADMA Biologics, Inc.
  • 5. AGC Biologics
  • 6. Ajinomoto Bio-Pharma Services
  • 7. Avid Bioservices, Inc.
  • 8. Baxter International, Inc
  • 9. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
  • 10. Cambrex Corporation
  • 11. Catalent, Inc.
  • 12. Emergent BioSolutions, Inc.
  • 13. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 14. JSR Life Sciences, LLC by JSR Group
  • 15. Kemwell Biopharma Pvt. Ltd.
  • 16. Lonza Group Ltd.
  • 17. Midas Pharma GmbH
  • 18. ProBioGen AG
  • 19. Recipharm AB
  • 20. Rentschler Biopharma SE
  • 21. Samsung Biologics
  • 22. Thermo Fisher Scientific, Inc.
  • 23. Toyobo Co. Ltd.
  • 24. Wacker Chemie AG
  • 25. WuXi Biologics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT HORMONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 197. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 198. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023